Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Aptose Biosciences Stock Sank Today

TheMotleyFool

0 0

Shares of Aptose Biosciences (NASDAQ: APTO) were sinking 11.9% as of 3:13 p.m. EDT on Monday. The decline came after the company presented preliminary clinical data from an early-stage clinical study evaluating CG-806 in treating relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), or non-Hodgkin lymphoma (NHL). The presentation was included in the American Association for Cancer Research (AACR) Virtual Annual Meeting.

Aptose's results included only limited information. The company said that the study has completed three dose levels with no drug-related severe adverse events reported so far.

Image source: Getty Images.

Source Fool.com

Like: 0

APTO

Share